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Transient response to nivolumab and relapse
after infliximab in a patient with primary
cutaneous CD8-positive aggressive
epidermotropic cytotoxic T-cell lymphoma
DOI: 10.1111/bjd.19470
DEAR EDITOR, Primary cutaneous CD8+ aggressive epider-
motropic T-cell lymphoma (CD8+ AECTCL) is a very rare sub-
type of cutaneous T-cell lymphoma. The frequency is less than
1% of all primary cutaneous lymphomas and prognosis is
poor, with a 5-year disease-specific survival rate of 31%.1
Because of the rarity of this entity, there are no evidence-
based treatment options.
We report the case of a 70-year-old female patient who
presented with a red plaque with central ulceration on the
left shin rapidly developing in 2 weeks. Skin biopsy revealed
atypical lymphoid cells in the epidermis and dermis with
atypical mitoses (Figure 1a). Immunohistochemical stains
showed reactivity with CD3, CD8 (Figure 1b), TIA-1 and
programmed cell death 1 ligand 1, with weak reactivity for
programmed cell death protein 1 (PD-1) expression. CD2,
CD4, CD20, CD30 and CD56 were negative. Cranial mag-
netic resonance imaging (MRI) and computed tomography
(CT) scan of neck, thorax and abdomen showed no evidence
of metastases. Bone marrow biopsy revealed no infiltration
with lymphoma cells, and blood count was normal. Primary
cutaneous CD8+ aggressive epidermotropic T-cell lymphoma
was diagnosed.
Chemotherapy with cyclophosphamide, doxorubicin, etopo-
side, vincristine and prednisone (CHOEP) every 21 days was
started. After six cycles of chemotherapy the plaque was
clearly regressive, and consolidating radiotherapy of the left
lower leg was started. Still on radiotherapy, the patient devel-
oped disseminated, well demarcated erythematous patches and
plaques, many with necrotic ulcerations, involving all extremi-
ties and trunk (Figure 1c), and ulceration on the hard palate.
Cranial MRI, CT scan and fluorescence-activated cell sorting
analysis ruled out extracutaneous manifestation. Pho-
tochemotherapy with psoralen plus ultraviolet A and treatment
with topical corticosteroids class IV were initiated without sig-
nificant improvement. Due to progression, therapy was chan-
ged to an anti-PD-1 antibody. After five infusions of
nivolumab (2 mg kg–1) the patient experienced near complete
remission of all lesions (Figure 1d). Only a singular new ery-
thematous plaque with no ulceration appeared on the trunk
during treatment. An additional skin biopsy was performed,
which showed similar findings to the initial diagnostic speci-
men. After seven infusions of nivolumab she developed
autoimmune diarrhoea grade 2 (Common Terminology Crite-
ria for Adverse Events). Therapy was paused and treatment
with prednisolone at 1 mg kg–1 orally was started and slowly
tapered. Owing to persistent symptoms, one infusion with a
tumour necrosis factor (TNF)-a inhibitor (infliximab)
5 mg kg–1 was applied. Diarrhoea improved and nivolumab
was restarted 1 month after cessation. However, in the follow-
ing 3 months, new disseminated erythematous and ulcerated
plaques appeared and the patient developed a painful massive
swelling in the preauricular region. MRI showed a mass in the
parotid lodge infiltrating the masseter muscle. Treatment was
switched to total body irradiation. However, the patient’s con-
dition deteriorated rapidly and she died from sepsis
14 months after diagnosis.
Checkpoint inhibitors play an increasing role in the treatment
of patients with solid and haematological malignancies. More
recent studies evaluated the safety and efficacy of anti-PD-1 anti-
bodies in patients with cutaneous T-cell lymphomas, including
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a phase Ib study for nivolumab that included 13 cases of myco-
sis fungoides and five cases of peripheral T-cell lymphoma. The
objective response rate in that study was 15% among patients
with mycosis fungoides and 40% among patients with periph-
eral T-cell lymphoma with no further specification of the sub-
type.2 A phase II study of 24 patients with pretreated mycosis
fungoides and Sezary syndrome showed an overall response rate
of 38%.3 To our knowledge, there are no descriptions of treat-
ment of CD8+ AECTCL with anti-PD-1 antibody. Reported treat-
ment regimens in cases of CD8+ AECTCL consist of
polychemotherapies with cyclophosphamide, doxorubicin, vin-
cristine and prednisone (CHOP). However, results are disap-
pointing, with limited success and often rapid recurrence.4
So far the most promising results were achieved with allo-
geneic hematopoietic stem cell transplantation with a possible
curative option,5,6 which was not possible in our patient
owing to rapid progression after multiagent chemotherapy,
age and comorbidity. Our patient initially responded surpris-
ingly well to therapy with anti-PD-1 antibody. However, after
a short duration of nearly complete remission she required
immunosuppressive medication including TNF-a inhibitor in
steroid-refractory immune-related diarrhoea. Subsequently, the
disease recurred with rapid progression and she finally died,
14 months after diagnosis of CD8+ AECTCL, due to sepsis.
There is ongoing discussion of whether treatment with TNF-a
inhibitors could induce progress of cutaneous lymphoma.7
Also in our case, it is not excluded that disease progression
was accelerated by anti-TNF-a treatment.
In conclusion, anti-PD-1 antibodies present a potential treat-
ment option for CD8+ AECTCL, an entity with otherwise few
options.
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Figure 1 (a) Intraepidermal and dermal multifocal infiltrates of atypical lymphocytes (haematoxylin and eosin staining; original
magnification 9 100). (b) Positive immunohistochemical staining for CD8 (original magnification 9 100). (c) Clinical image before starting
treatment with nivolumab and (d) after five infusions of nivolumab.
© 2020 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists
British Journal of Dermatology (2021) 184, pp340–373
346 Research letters
6 Liu V, Cutler CS, Young AZ. Case records of the Massachusetts Gen-
eral Hospital. Case 38–2007. A 44-year-old woman with general-
ized, painful, ulcerated skin lesions. N Engl J Med 2007; 357:
2496–505.
7 Martinez-Escala ME, Posligua AL, Wickless H et al. Progression of
undiagnosed cutaneous lymphoma after anti-tumor necrosis factor-
alpha therapy. J Am Acad Dermatol 2018; 78:1068–76.
Funding sources: none.
Conflicts of interest: F.T. received travel grants from Novartis and
AbbVie; R.D. has intermittent, project-focused consulting and/or advi-
sory relationships with Novartis, Merck Sharp & Dohme (MSD), Bristol
Myers Squibb (BMS), Roche, Amgen, Takeda, Pierre Fabre, Sun
Pharma and Sanofi outside the submitted work; and L.H. received
grants from Novartis, and personal fees from Amgen, MSD, BMS,
Roche, Curevac, Pierre Fabre, Novartis and Sanofi outside the submit-
ted work.
Recurrent MVD mutation in European patients
with disseminated porokeratosis
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DEAR EDITOR, Porokeratosis comprises clinically and genetically
heterogeneous disorders of keratinization. They manifest
with marginate scaling lesions, histologically showing a col-
umn of parakeratotic keratinocytes, the cornoid lamella.
Porokeratotic conditions were historically classified into sev-
eral clinical forms based on the distribution and morphol-
ogy of the lesions, for example disseminated porokeratoses,
porokeratosis of Mibelli, giant porokeratosis, palmoplantar
porokeratosis Mantoux and linear porokeratosis. Several clini-
cal forms are associated with second-hit genetic changes in
the presence of monoallelic germline mutations in genes
encoding enzymes of the mevalonate pathway (MVK, PMVK,
MVD and FDPS), suggesting therefore common pathogenetic
mechanisms.1–5 In addition, mutations in other genes, such
as SLC17A96 and SSH1,7 have been reported in disseminated
porokeratosis.
The terminology making use of eponyms and descriptive
terms is confusing and requires thorough revision based on
recent molecular genetic data. The treatment of porokeratoses
is challenging due to the modest therapeutic response to clas-
sical measures (e.g. keratolytics and retinoids) and to the mul-
titude of lesions, which spread over large body areas.
Pathogenetic-based topical treatment with statins that target
the mevalonate pathway and cholesterol biosynthesis was
recently shown to be effective in disseminated porokeratosis.8
Here we performed molecular genetic analysis of skin sam-
ples of eight patients with disseminated porokeratosis. All
patients were white with skin phototype I or II. Three had a
positive family history of porokeratosis, and the other cases
Figure 1 Clinical manifestations before and after treatment with simvastatin ointment in patient 1. (a) Before treatment, the patient presented
porokeratotic lesions on the arms and legs. (b) After 2 months of treatment of the right arm and leg (green frame) with an ointment containing
simvastatin the lesions almost disappeared. She noticed the benefit only after the first 3 weeks of treatment. The left side of the body was treated
with moisturizer.
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